New pain pill HRS-6257 enters first human tests

NCT ID NCT07301333

Recruiting now Symptom relief Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study is testing a new drug, HRS-6257, in 80 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo, and researchers will monitor side effects and measure drug levels in the blood. The study also looks at how food affects the drug and includes a cold pain test to get an early read on pain response, but it is not designed to prove the drug works for pain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-6257
What this could lead to: If successful, this could point toward a new oral pain medication.
What could go wrong: This is a very early Phase 1 study in healthy people, not patients. It only tests safety and how the drug moves through the body, not whether it actually relieves pain. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAIN

Contacts and locations

Locations

Third Xiangya Hospital of Central South University
RECRUITING

Changsha, Hunan, 410013, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.